Mankind Pharma Ltd (MANKIND) - Net Assets
Based on the latest financial reports, Mankind Pharma Ltd (MANKIND) has net assets worth Rs155.29 Billion INR (≈ $1.68 Billion USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs288.13 Billion ≈ $3.12 Billion USD) and total liabilities (Rs132.85 Billion ≈ $1.44 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Mankind Pharma Ltd's assets to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs155.29 Billion |
| % of Total Assets | 53.89% |
| Annual Growth Rate | 30.26% |
| 5-Year Change | 199.58% |
| 10-Year Change | N/A |
| Growth Volatility | 10.35 |
Mankind Pharma Ltd - Net Assets Trend (2019–2025)
This chart illustrates how Mankind Pharma Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is Mankind Pharma Ltd's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Mankind Pharma Ltd (2019–2025)
The table below shows the annual net assets of Mankind Pharma Ltd from 2019 to 2025. For live valuation and market cap data, see MANKIND company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs145.68 Billion ≈ $1.58 Billion |
+52.14% |
| 2024-03-31 | Rs95.76 Billion ≈ $1.04 Billion |
+25.19% |
| 2023-03-31 | Rs76.49 Billion ≈ $827.19 Million |
+21.10% |
| 2022-03-31 | Rs63.16 Billion ≈ $683.08 Million |
+29.89% |
| 2021-03-31 | Rs48.63 Billion ≈ $525.90 Million |
+32.45% |
| 2020-03-31 | Rs36.72 Billion ≈ $397.07 Million |
+23.14% |
| 2019-03-31 | Rs29.82 Billion ≈ $322.46 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Mankind Pharma Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 226.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs119.07 Billion | 83.08% |
| Common Stock | Rs412.60 Million | 0.29% |
| Other Comprehensive Income | Rs-6.24 Billion | -4.35% |
| Other Components | Rs30.08 Billion | 20.98% |
| Total Equity | Rs143.32 Billion | 100.00% |
Mankind Pharma Ltd Competitors by Market Cap
The table below lists competitors of Mankind Pharma Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Brookfield Renewable Partners L.P
TO:BEP-UN
|
$10.04 Billion |
|
Pro Medicus Ltd
AU:PME
|
$10.06 Billion |
|
Embraer S.A
F:EMY
|
$10.07 Billion |
|
Skyverse Technology Co. Ltd. A
SHG:688361
|
$10.07 Billion |
|
Komercni Banka A.S.
PR:KOMB
|
$10.02 Billion |
|
Wintrust Financial Corporation
NASDAQ:WTFC
|
$10.02 Billion |
|
Aegon NV
AS:AGN
|
$10.02 Billion |
|
NTPC Green Energy Limited
NSE:NTPCGREEN
|
$10.01 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mankind Pharma Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 93,630,881,000 to 143,323,900,000, a change of 49,693,019,000 (53.1%).
- Net income of 19,909,600,000 contributed positively to equity growth.
- Other comprehensive income increased equity by 141,946,000.
- Other factors increased equity by 29,641,473,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs19.91 Billion | +13.89% |
| Other Comprehensive Income | Rs141.95 Million | +0.1% |
| Other Changes | Rs29.64 Billion | +20.68% |
| Total Change | Rs- | 53.07% |
Book Value vs Market Value Analysis
This analysis compares Mankind Pharma Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.34x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 31.88x to 6.34x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-03-31 | Rs70.47 | Rs2246.70 | x |
| 2020-03-31 | Rs87.00 | Rs2246.70 | x |
| 2021-03-31 | Rs117.88 | Rs2246.70 | x |
| 2022-03-31 | Rs153.65 | Rs2246.70 | x |
| 2023-03-31 | Rs185.61 | Rs2246.70 | x |
| 2024-03-31 | Rs233.40 | Rs2246.70 | x |
| 2025-03-31 | Rs354.18 | Rs2246.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mankind Pharma Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.89%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.31%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 1.94x
- Recent ROE (13.89%) is below the historical average (21.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 20.49% | 11.62% | 1.21x | 1.46x | Rs2.96 Billion |
| 2020 | 29.56% | 17.57% | 1.16x | 1.46x | Rs6.82 Billion |
| 2021 | 26.80% | 20.36% | 0.98x | 1.35x | Rs7.93 Billion |
| 2022 | 23.29% | 18.42% | 0.85x | 1.49x | Rs8.18 Billion |
| 2023 | 17.24% | 14.66% | 0.90x | 1.31x | Rs5.38 Billion |
| 2024 | 20.43% | 18.51% | 0.86x | 1.28x | Rs9.77 Billion |
| 2025 | 13.89% | 16.31% | 0.44x | 1.94x | Rs5.58 Billion |
Industry Comparison
This section compares Mankind Pharma Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $23,713,303,062
- Average return on equity (ROE) among peers: 8.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mankind Pharma Ltd (MANKIND) | Rs155.29 Billion | 20.49% | 0.86x | $10.03 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $988.60 Million | 6.59% | 1.36x | $27.93 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $6.52 Billion | 21.67% | 1.42x | $371.43 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $19.90 Billion | 13.69% | 0.46x | $725.68 Million |
| Abbott India Limited (ABBOTINDIA) | $36.99 Billion | 32.48% | 0.40x | $5.85 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $1.16 Billion | 12.69% | 1.32x | $3.81 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $6.25 Billion | -40.39% | 3.91x | $906.19 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $6.98 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.46 Billion | 16.82% | 0.29x | $178.52 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $51.90 Billion | 11.24% | 0.50x | $1.60 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $23.50 Billion | -5.26% | 1.65x | $8.73 Billion |
About Mankind Pharma Ltd
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory d… Read more